Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds

Diego Carrella, Isabella Manni, Barbara Tumaini, Rosanna Dattilo, Federica Papaccio, Margherita Mutarelli, Francesco Sirci, Carla A. Amoreo, Marcella Mottolese, Manuela Iezzi, Laura Ciolli, Valentina Aria, Roberta Bosotti, Antonella Isacchi, Fabrizio Loreni, Alberto Bardelli, Vittorio E. Avvedimento, Diego di Bernardo, Luca Cardone

Research output: Contribution to journalArticle

Abstract

The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a "reverse" oncogene-specific signature might assist in the computational repositioning of inhibitors of oncogenic pathways. As a proof of principle, we focused on oncogenic PI3K-dependent signalling, a molecular pathway frequently driving cancer progression as well as raising resistance to anticancer-targeted therapies. We show that implementation of "reverse" oncogenic PI3K-dependent transcriptional signatures combined with interrogation of drug networks identified inhibitors of PI3K-dependent signalling among FDA-approved compounds. This led to repositioning of Niclosamide (Niclo) and Pyrvinium Pamoate (PP), two anthelmintic drugs, as inhibitors of oncogenic PI3K-dependent signalling. Niclo inhibited phosphorylation of P70S6K, while PP inhibited phosphorylation of AKT and P70S6K, which are downstream targets of PI3K. Anthelmintics inhibited oncogenic PI3K-dependent gene expression and showed a cytostatic effect in vitro and in mouse mammary gland. Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations. Our data indicate that drug repositioning by network analysis of oncogene-specific transcriptional signatures is an efficient strategy for communityidentifying oncogenic pathway inhibitors among FDA-approved compounds. We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.

Original languageEnglish
Pages (from-to)58743-58758
Number of pages16
JournalOncotarget
Volume7
Issue number37
DOIs
Publication statusPublished - 2016

Fingerprint

Drug Repositioning
70-kDa Ribosomal Protein S6 Kinases
Phosphatidylinositol 3-Kinases
Niclosamide
Anthelmintics
Oncogenes
Phosphorylation
Pharmaceutical Preparations
Neoplasms
Mutation
Cytostatic Agents
Therapeutics
Human Mammary Glands
Transcriptome
Breast Neoplasms
Gene Expression

Keywords

  • Drugs network
  • FDA-approved drugs
  • Gene expression signatures
  • Oncogenes
  • PI3K-dependent pathways

ASJC Scopus subject areas

  • Oncology

Cite this

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds. / Carrella, Diego; Manni, Isabella; Tumaini, Barbara; Dattilo, Rosanna; Papaccio, Federica; Mutarelli, Margherita; Sirci, Francesco; Amoreo, Carla A.; Mottolese, Marcella; Iezzi, Manuela; Ciolli, Laura; Aria, Valentina; Bosotti, Roberta; Isacchi, Antonella; Loreni, Fabrizio; Bardelli, Alberto; Avvedimento, Vittorio E.; di Bernardo, Diego; Cardone, Luca.

In: Oncotarget, Vol. 7, No. 37, 2016, p. 58743-58758.

Research output: Contribution to journalArticle

Carrella, D, Manni, I, Tumaini, B, Dattilo, R, Papaccio, F, Mutarelli, M, Sirci, F, Amoreo, CA, Mottolese, M, Iezzi, M, Ciolli, L, Aria, V, Bosotti, R, Isacchi, A, Loreni, F, Bardelli, A, Avvedimento, VE, di Bernardo, D & Cardone, L 2016, 'Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds', Oncotarget, vol. 7, no. 37, pp. 58743-58758. https://doi.org/10.18632/oncotarget.11318
Carrella, Diego ; Manni, Isabella ; Tumaini, Barbara ; Dattilo, Rosanna ; Papaccio, Federica ; Mutarelli, Margherita ; Sirci, Francesco ; Amoreo, Carla A. ; Mottolese, Marcella ; Iezzi, Manuela ; Ciolli, Laura ; Aria, Valentina ; Bosotti, Roberta ; Isacchi, Antonella ; Loreni, Fabrizio ; Bardelli, Alberto ; Avvedimento, Vittorio E. ; di Bernardo, Diego ; Cardone, Luca. / Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds. In: Oncotarget. 2016 ; Vol. 7, No. 37. pp. 58743-58758.
@article{135e26aa06d847ffba665e2ff9a1371b,
title = "Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds",
abstract = "The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a {"}reverse{"} oncogene-specific signature might assist in the computational repositioning of inhibitors of oncogenic pathways. As a proof of principle, we focused on oncogenic PI3K-dependent signalling, a molecular pathway frequently driving cancer progression as well as raising resistance to anticancer-targeted therapies. We show that implementation of {"}reverse{"} oncogenic PI3K-dependent transcriptional signatures combined with interrogation of drug networks identified inhibitors of PI3K-dependent signalling among FDA-approved compounds. This led to repositioning of Niclosamide (Niclo) and Pyrvinium Pamoate (PP), two anthelmintic drugs, as inhibitors of oncogenic PI3K-dependent signalling. Niclo inhibited phosphorylation of P70S6K, while PP inhibited phosphorylation of AKT and P70S6K, which are downstream targets of PI3K. Anthelmintics inhibited oncogenic PI3K-dependent gene expression and showed a cytostatic effect in vitro and in mouse mammary gland. Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations. Our data indicate that drug repositioning by network analysis of oncogene-specific transcriptional signatures is an efficient strategy for communityidentifying oncogenic pathway inhibitors among FDA-approved compounds. We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.",
keywords = "Drugs network, FDA-approved drugs, Gene expression signatures, Oncogenes, PI3K-dependent pathways",
author = "Diego Carrella and Isabella Manni and Barbara Tumaini and Rosanna Dattilo and Federica Papaccio and Margherita Mutarelli and Francesco Sirci and Amoreo, {Carla A.} and Marcella Mottolese and Manuela Iezzi and Laura Ciolli and Valentina Aria and Roberta Bosotti and Antonella Isacchi and Fabrizio Loreni and Alberto Bardelli and Avvedimento, {Vittorio E.} and {di Bernardo}, Diego and Luca Cardone",
year = "2016",
doi = "10.18632/oncotarget.11318",
language = "English",
volume = "7",
pages = "58743--58758",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "37",

}

TY - JOUR

T1 - Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDAapproved compounds

AU - Carrella, Diego

AU - Manni, Isabella

AU - Tumaini, Barbara

AU - Dattilo, Rosanna

AU - Papaccio, Federica

AU - Mutarelli, Margherita

AU - Sirci, Francesco

AU - Amoreo, Carla A.

AU - Mottolese, Marcella

AU - Iezzi, Manuela

AU - Ciolli, Laura

AU - Aria, Valentina

AU - Bosotti, Roberta

AU - Isacchi, Antonella

AU - Loreni, Fabrizio

AU - Bardelli, Alberto

AU - Avvedimento, Vittorio E.

AU - di Bernardo, Diego

AU - Cardone, Luca

PY - 2016

Y1 - 2016

N2 - The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a "reverse" oncogene-specific signature might assist in the computational repositioning of inhibitors of oncogenic pathways. As a proof of principle, we focused on oncogenic PI3K-dependent signalling, a molecular pathway frequently driving cancer progression as well as raising resistance to anticancer-targeted therapies. We show that implementation of "reverse" oncogenic PI3K-dependent transcriptional signatures combined with interrogation of drug networks identified inhibitors of PI3K-dependent signalling among FDA-approved compounds. This led to repositioning of Niclosamide (Niclo) and Pyrvinium Pamoate (PP), two anthelmintic drugs, as inhibitors of oncogenic PI3K-dependent signalling. Niclo inhibited phosphorylation of P70S6K, while PP inhibited phosphorylation of AKT and P70S6K, which are downstream targets of PI3K. Anthelmintics inhibited oncogenic PI3K-dependent gene expression and showed a cytostatic effect in vitro and in mouse mammary gland. Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations. Our data indicate that drug repositioning by network analysis of oncogene-specific transcriptional signatures is an efficient strategy for communityidentifying oncogenic pathway inhibitors among FDA-approved compounds. We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.

AB - The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a "reverse" oncogene-specific signature might assist in the computational repositioning of inhibitors of oncogenic pathways. As a proof of principle, we focused on oncogenic PI3K-dependent signalling, a molecular pathway frequently driving cancer progression as well as raising resistance to anticancer-targeted therapies. We show that implementation of "reverse" oncogenic PI3K-dependent transcriptional signatures combined with interrogation of drug networks identified inhibitors of PI3K-dependent signalling among FDA-approved compounds. This led to repositioning of Niclosamide (Niclo) and Pyrvinium Pamoate (PP), two anthelmintic drugs, as inhibitors of oncogenic PI3K-dependent signalling. Niclo inhibited phosphorylation of P70S6K, while PP inhibited phosphorylation of AKT and P70S6K, which are downstream targets of PI3K. Anthelmintics inhibited oncogenic PI3K-dependent gene expression and showed a cytostatic effect in vitro and in mouse mammary gland. Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations. Our data indicate that drug repositioning by network analysis of oncogene-specific transcriptional signatures is an efficient strategy for communityidentifying oncogenic pathway inhibitors among FDA-approved compounds. We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.

KW - Drugs network

KW - FDA-approved drugs

KW - Gene expression signatures

KW - Oncogenes

KW - PI3K-dependent pathways

UR - http://www.scopus.com/inward/record.url?scp=84991386993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991386993&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11318

DO - 10.18632/oncotarget.11318

M3 - Article

AN - SCOPUS:84991386993

VL - 7

SP - 58743

EP - 58758

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -